Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06533813 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

Study acronym: ERNEST-3
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion pushed from Dec 19, 2025 to Dec 31, 2028
    • Trial sites reduced: 36 → 27 locations
    v6
  2. Primary completion date changed from estimate of Dec 31, 2025 to Dec 19, 2025
    • Site details revised at 15 of 36 sites
    v5
  3. Primary completion date: Dec 31, 2024 to Dec 31, 2025v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 30, 2024 to Oct 14, 2024
    • Site details revised at 36 of 36 sites
    v3
  5. Start date: Aug 1, 2024 to Sep 30, 2024v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.
Trial Details
NCT Number NCT06533813
Lead Sponsor FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Collaborators: GlaxoSmithKline
Conditions
(from sponsor)		 Myelofibrosis
Related terms Primary Myelofibrosis
Enrollment 617 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov